Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma

International Journal of Molecular Medicine

Volumn 32, Issue 3, 2013, Pages 557-567

  Chen, Junying ^a   Yao, Desheng ^a   Li, Yue ^b   Chen, Hong ^a   He, Chanjuan ^a   Ding, Nan ^a   Lu, Yan ^a   Ou, Tingyu ^a   Zhao, Shan ^a   Li, Li ^a   Long, Fengyi ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Cervical squamous cell carcinoma; Lymph node metastasis; MicroRNA; Serum marker

Indexed keywords

MICRORNA; MICRORNA 1246; MICRORNA 20A; MICRORNA 2392; MICRORNA 3147; MICRORNA 3162 5P; MICRORNA 4484; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; UPREGULATION; UTERINE CERVIX CARCINOMA;

CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MICRORNAS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84880399358     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1424     Document Type: Article

References (59)

1. Hu X, Schwarz JK, Lewis JS Jr, et al: A microRNA expression signature for cervical cancer prognosis. Cancer Res 70: 1441-1448, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Sturgeon CM, Duffy MJ, Hofmann BR, et al: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 56: e1-e48, 2010.
4. Hacker NF: Cervical cancer. In: Practical Gynecologic Oncology. Berek JS and Hacker NF (eds). 3rd edition, Lippincott Williams and Wilkins, Philadelphia, PA, pp345-405, 2000.
5. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 39: 2470-2486, 2003.
6. Lee YY, Choi CH, Sung CO, et al: Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol 124: 92-97, 2012.
7. Huang EY, Wang CJ, Chen HC, et al: Multivariate analysis of para-aortic lymph node recurrence after definitive radiotherapy for stage IB-IVA squamous cell carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 72: 834-842, 2008.
8. Ogino I, Nakayama H, Okamoto N, Kitamura T and Inoue T: The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy. Int J Gynecol Cancer 16: 1094-1100, 2006.
9. Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S and Hiramatsu Y: The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix. Gynecol Oncol 119: 81-86, 2010.
10. van de Lande J, Davelaar EM, von Mensdorff-Pouilly S, et al: SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer. Gynecol Oncol 112: 119-125, 2009.
11. Matsuda H, Mori M, Tsujitani S, Ohno S, Kuwano H and Sugimachi K: Immunohistochemical evaluation of squamous cell carcinoma antigen and S-100 protein-positive cells in human malignant esophageal tissues. Cancer 65: 2261-2265, 1990.
12. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K and Banas T: Upregulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett 249: 171-177, 2007.
13. Gaarenstroom KN, Bonfrer JM, Korse CM, Kenter GG and Kenemans P: Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. Anticancer Res 17: 2955-2958, 1997.
14. Chen J, Yao D and Wu Z: Diagnostic value of serum squamous cell carcinoma antigen on lymphatic metastasis in early-stage cervical cancer: a meta-analysis. Cancer Res Prev Treat 39: 811-817, 2012 (In Chinese).
15. Enfield KS, Stewart GL, Pikor LA, et al: MicroRNA gene dosage alterations and drug response in lung cancer. J Biomed Biotechnol 2011: 474632, 2011.
16. Medina PP, Nolde M and Slack FJ: OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467: 86-90, 2010.
17. Wang XW, Heegaard NH and Orum H: MicroRNAs in liver disease. Gastroenterology 142: 1431-1443, 2012.
18. Liu R, Chen X, Du Y, et al: Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 58: 610-618, 2012.
19. Jurmeister S, Baumann M, Balwierz A, et al: MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol 32: 633-651, 2012.
20. Hennessey PT, Sanford T, Choudhary A, et al: Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 7: e32307, 2012.
21. Wu Q, Lu Z, Li H, Lu J, Guo L and Ge Q: Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol 2011: 597145, 2011.
22. Santos CF, Kurhanewicz J, Tabatabai ZL, et al: Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed 23: 391-398, 2010.
23. Hsieh CH, Rau CS, Jeng JC, et al: Whole blood-derived microRNA signatures in mice exposed to lipopolysaccharides. J Biomed Sci 19: 69, 2012.
24. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN and Beretta L: Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6: e23937, 2011.
25. Hu Z, Chen X, Zhao Y, et al: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28: 1721-1726, 2010.
26. Wulfken LM, Moritz R, Ohlmann C, et al: MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6: e25787, 2011.
27. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
28. Jamieson NB, Morran DC, Morton JP, et al: MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18: 534-545, 2012.
29. Bihrer V, Waidmann O, Friedrich-Rust M, et al: Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 6: e26971, 2011.
30. Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V and Pantel K: Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat 134: 933-941, 2012.
31. Roth C, Kasimir-Bauer S, Pantel K and Schwarzenbach H: Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 5: 281-291, 2011.
32. Li C, Li JF, Cai Q, et al: MiRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol: Sep 7, 2012 (Epub ahead of print).
33. Yu S, Liu Y, Wang J, et al: Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 97: 2084-2092, 2012.
34. Sakuragi N: Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol 12: 165-175, 2007.
35. Juang CM, Wang PH, Yen MS, Lai CR, Ng HT and Yuan CC: Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol 76: 103-106, 2000.
36. Gaarenstroom KN, Kenter GG, Bonfrer JM, et al: Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol 77: 164-170, 2000.
37. Tian RQ, Wang XH, Hou LJ, et al: MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J Biol Chem 286: 25556-25563, 2011.
38. Au Yeung CL, Tsang TY, Yau PL and Kwok TT: Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/ urokinase-type plasminogen activator pathway. Oncogene 30: 2401-2410, 2011.
39. Deftereos G, Corrie SR, Feng Q, et al: Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One 6: e28423, 2011.
40. Pang RT, Leung CO, Ye TM, et al: MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 31: 1037-1044, 2010.
41. Kang HW, Wang F, Wei Q, et al: miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett 586: 897-904, 2012.
42. Zhang Y, Liao JM, Zeng SX and Lu H: p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep 12: 811-817, 2011.
43. Liao JM, Zhou X, Zhang Y and Lu H: MiR-1246: a new link of the p53 family with cancer and Down syndrome. Cell Cycle 11: 2624-2630, 2012.
44. Baek KH, Zaslavsky A, Lynch RC, et al: Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459: 1126-1130, 2009.
45. Pigati L, Yaddanapudi SC, Iyengar R, et al: Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 5: e13515, 2010.
46. Baraniskin A, Nopel-Dunnebacke S, Ahrens M, et al: Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer 132: E48-E57, 2013.
47. Matsubara H, Takeuchi T, Nishikawa E, et al: Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 26: 6099-6105, 2007.
48. Huang G, Nishimoto K, Zhou Z, Hughes D and Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 72: 908-916, 2012.
49. Fan X, Liu Y, Jiang J, et al: miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim Biophys Sin (Shanghai) 42: 318-324, 2010.
50. Chai H, Liu M, Tian R, Li X and Tang H: miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 43: 217-225, 2011.
51. Zhang M, Liu Q, Mi S, et al: Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J Immunol 186: 4716-4724, 2011.
52. Li X, Pan JH, Song B, et al: Suppression of CX43 expression by miR-20a in the progression of human prostate cancer. Cancer Biol Ther 13: 890-898, 2012.
53. Wang W, Feng L, Zhang H, et al: Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta. J Clin Endocrinol Metab 97: E1051-E1059, 2012.
54. Poliseno L, Pitto L, Simili M, et al: The proto-oncogene LRF is under post-transcriptional control of MiR-20a: implications for senescence. PLoS One 3: e2542, 2008.
55. Wu H, Wang F, Hu S, et al: MiR-20a and miR-106b negatively regulate autophagy induced by leucine deprivation via suppression of ULK1 expression in C2C12 myoblasts. Cell Signal 24: 2179-2186, 2012.
56. Elkayam E, Kuhn CD, Tocilj A, et al: The structure of human argonaute-2 in complex with miR-20a. Cell 150: 100-110, 2012.
57. Stark MS, Tyagi S, Nancarrow DJ, et al: Characterization of the melanoma miRNAome by deep sequencing. PLoS One 5: e9685, 2010.
58. Persson H, Kvist A, Rego N, et al: Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 71: 78-86, 2011.
59. Jima DD, Zhang J, Jacobs C, et al: Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 116: e118-e127, 2010.